Non-randomised phase II trials of drug combinations: often meaningless, sometimes misleading. Are there alternative strategies?

[1]  K. Antman.  A critique of the eleven randomised trials of high-dose chemotherapy for breast cancer. , 2001, European journal of cancer.

[2]  T M Grogan,et al.  Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.

[3]  L. Gordon,et al.  Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma. , 1992, The New England journal of medicine.

[4]  B. Baron,et al.  Results of a randomised phase II study of cisplatin plus 5-fluorouracil versus cisplatin plus 5-fluorouracil with alpha-interferon in metastatic pancreatic cancer: an EORTC gastrointestinal tract cancer group trial. , 2002, European journal of cancer.

[5]  T. Brennan,et al.  The controversy over high-dose chemotherapy with autologous bone marrow transplant for breast cancer. , 2001, Health affairs.

[6]  T. Welte,et al.  Gemcitabine, vinorelbine and cisplatin combination chemotherapy in advanced non-small cell lung cancer: a phase II trial. , 2002, European journal of cancer.

[7]  R. Bast,et al.  High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  R. Mick,et al.  High-dose consolidation therapy with autologous stem cell rescue in stage IV breast cancer. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[10]  G. Rosner,et al.  High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  M. van Glabbeke,et al.  Statistical methodology of phase III cancer clinical trials: advances and future perspectives. , 2002, European journal of cancer.

[12]  A. López-Guillermo,et al.  CHOP vs. ProMACE‐CytaBOM in the treatment of aggressive non‐Hodgkin's lymphomas: long‐term results of a multicenter randomized trial , 1996, European journal of haematology.

[13]  treatment division,et al.  Phase II trials in the EORTC , 1997 .

[14]  J. Matthews,et al.  Randomized comparison of MACOP-B with CHOP in patients with intermediate-grade non-Hodgkin's lymphoma. The Australian and New Zealand Lymphoma Group. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  C. de Wolf‐Peeters,et al.  EORTC study of non-Hodgkin's lymphoma: phase III study comparing CHVmP-VB and ProMACE-MOPP in patients with stage II, III, and IV intermediate- and high-grade lymphoma. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  R. Fisher,et al.  Unfavorable histologies of non-Hodgkin's lymphoma treated with ProMACE-CytaBOM: a groupwide Southwest Oncology Group study. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  A. Luini,et al.  Efficacy, toxicity, and applicability of high-dose sequential chemotherapy as adjuvant treatment in operable breast cancer with 10 or more involved axillary nodes: five-year results. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  C. Tournigand,et al.  Optimisation of 5-fluorouracil (5-FU)/cisplatin combination chemotherapy with a new schedule of hydroxyurea, leucovorin, 5-FU and cisplatin (HLFP regimen) for metastatic oesophageal cancer. , 2002, European journal of cancer.

[19]  R. Fisher,et al.  Diffuse aggressive lymphomas: increased survival after alternating flexible sequences of proMACE and MOPP chemotherapy. , 1983, Annals of internal medicine.

[20]  T. Miller,et al.  Treatment of diffuse large-cell lymphoma: a summary of outcome for patients treated by Southwest Oncology Group. , 1993, Cancer treatment and research.

[21]  R. Theriault,et al.  High-dose chemotherapy for high-risk primary breast cancer: an on-site review of the Bezwoda study , 2000, The Lancet.

[22]  G. Pinkus,et al.  Improved prognosis of diffuse histiocytic and undifferentiated lymphoma by use of high dose methotrexate alternating with standard agents (M-BACOD). , 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  G. Pinkus,et al.  The m-BACOD combination chemotherapy regimen in large-cell lymphoma: analysis of the completed trial and comparison with the M-BACOD regimen. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  J. Connors,et al.  MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma. , 1985, Annals of internal medicine.

[25]  C. Hudis,et al.  An on-site audit of the South African trial of high-dose chemotherapy for metastatic breast cancer and associated publications. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.